The Journal of Immunology, Vol 150, Issue 2 331-341, Copyright © 1993 by American Association of Immunologists

ARTICLES

The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition

WH Boehncke, T Takeshita, CD Pendleton, RA Houghten, S Sadegh-Nasseri, L Racioppi, JA Berzofsky and RN Germain
Lymphocyte Biology Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.

Previous studies on the role of specific residues of the peptide or MHC molecule in Ag presentation have revealed the sensitivity of this complex system to even small changes in structure. In our study, we have analyzed the effect of amino acid substitution in a major CD4+ T cell determinant (T1) of HIV-1 gp160 on binding and recognition in the context of various E alpha E beta MHC class II molecules. Individual alanine substitutions at all but three positions had little or no negative effect on either MHC binding or recognition by a specific T hybridoma, whereas substitutions with larger side chains often diminished reactivity. A poly-alanine peptide containing only four of the original residues was an effective MHC class II binder and in vivo immunogen, although lacking the ability to stimulate the hybridoma. Replacement of a glutamic acid in T1 with alanine or a size- conservative, uncharged glutamine, but not a negatively charged aspartic acid produced a peptide at least 100-fold more potent than the parent peptide, indicating an inhibitory effect of the negative charge. Conversely, substitution of a glutamic acid for valine at position 29 in the floor of the peptide binding site of the E alpha E beta molecule decreased functional presentation of this peptide by more than 2 logs. However, these two effects of glutamic acid were not complementary and were mediated by distinct mechanisms, as the change in the peptide altered the extent of binding to class II, but the change in the MHC molecule decreased recognition without inhibiting peptide binding. Taken together, the data all suggest the conclusion that changes in side-chains of peptides and MHC molecules affect Ag presentation and T cell stimulation most often by introducing dominant negative or interfering groups that prevent or alter the pattern of binding events primarily mediated by a very limited number of other residues in the Ag or presenting molecule. These results have important implications for understanding the biochemistry of peptide-MHC-TCR interactions and for the possible design of vaccines both more potent and less subject to allele-specific limitations on immunogenicity.

This article has been cited by other articles:

				Y. Nakagawa, H. Kikuchi, and H. Takahashi Molecular Analysis of TCR and Peptide/MHC Interaction Using P18-I10-Derived Peptides with a Single D-Amino Acid Substitution Biophys. J., April 1, 2007; 92(7): 2570 - 2582. [Abstract] [Full Text] [PDF]

				T. Okazaki, C. D. Pendleton, P. Sarobe, E. K. Thomas, S. Iyengar, C. Harro, D. Schwartz, and J. A. Berzofsky Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine J. Immunol., March 15, 2006; 176(6): 3753 - 3759. [Abstract] [Full Text] [PDF]

				L. T. van den Broeke, C. D. Pendleton, C. Mackall, L. J. Helman, and J. A. Berzofsky Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors Cancer Res., February 1, 2006; 66(3): 1818 - 1823. [Abstract] [Full Text] [PDF]

				N. J. Felix, A. Suri, J. J. Walters, S. Horvath, M. L. Gross, and P. M. Allen I-Ep-Bound Self-Peptides: Identification, Characterization, and Role in Alloreactivity J. Immunol., January 15, 2006; 176(2): 1062 - 1071. [Abstract] [Full Text] [PDF]

				Y. Xu, S. J. Gendler, and A. Franco Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas J. Exp. Med., March 1, 2004; 199(5): 707 - 716. [Abstract] [Full Text] [PDF]

				Z. Zavala-Ruiz, E. J. Sundberg, J. D. Stone, D. B. DeOliveira, I. C. Chan, J. Svendsen, R. A. Mariuzza, and L. J. Stern Exploration of the P6/P7 Region of the Peptide-binding Site of the Human Class II Major Histocompatability Complex Protein HLA-DR1 J. Biol. Chem., November 7, 2003; 278(45): 44904 - 44912. [Abstract] [Full Text] [PDF]

				T. Okazaki, C. D. Pendleton, F. Lemonnier, and J. A. Berzofsky Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen J. Immunol., September 1, 2003; 171(5): 2548 - 2555. [Abstract] [Full Text] [PDF]

				T. K. Hoffmann, D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope J. Immunol., February 1, 2002; 168(3): 1338 - 1347. [Abstract] [Full Text] [PDF]

				R. R. Latek, S. J. Petzold, and E. R. Unanue Hindering auxiliary anchors are potent modulators of peptide binding and selection by I-Ak class II molecules PNAS, September 29, 2000; (2000) 210384197. [Abstract] [Full Text]

				B. Hemmer, T. Kondo, B. Gran, C. Pinilla, I. Cortese, J. Pascal, A. Tzou, H. F. McFarland, R. Houghten, and R. Martin Minimal peptide length requirements for CD4+ T cell clones--implications for molecular mimicry and T cell survival Int. Immunol., March 1, 2000; 12(3): 375 - 383. [Abstract] [Full Text] [PDF]

				S. Calbo, G. Guichard, P. Bousso, S. Muller, P. Kourilsky, J.-P. Briand, and J.-P. Abastado Role of Peptide Backbone in T Cell Recognition J. Immunol., April 15, 1999; 162(8): 4657 - 4662. [Abstract] [Full Text] [PDF]

				A. Franco, T. Yokoyama, D. Huynh, C. Thomson, S. G. Nathenson, and H. M. Grey Fine Specificity and MHC Restriction of Trinitrophenyl- Specific CTL J. Immunol., March 15, 1999; 162(6): 3388 - 3394. [Abstract] [Full Text] [PDF]

				R. Dyall, W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic Heteroclitic Immunization Induces Tumor Immunity J. Exp. Med., November 2, 1998; 188(9): 1553 - 1561. [Abstract] [Full Text] [PDF]

				C. Lekutis and N. L. Letvin Substitutions in a Major Histocompatibility Complex Class II-Restricted Human Immunodeficiency Virus Type 1 gp120 Epitope Can Affect CD4+ T-Helper-Cell Function J. Virol., July 1, 1998; 72(7): 5840 - 5844. [Abstract] [Full Text] [PDF]

				J. D. Ahlers, T. Takeshita, C. D. Pendleton, and J. A. Berzofsky Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence PNAS, September 30, 1997; 94(20): 10856 - 10861. [Abstract] [Full Text] [PDF]

				R. R. Latek, S. J. Petzold, and E. R. Unanue Hindering auxiliary anchors are potent modulators of peptide binding and selection by I-Ak class II molecules PNAS, October 10, 2000; 97(21): 11460 - 11465. [Abstract] [Full Text] [PDF]